Inflyuvak

General characteristics. Structure:

Active agent: one dose of a vaccine (0,5 ml) contain hemagglutinin (HECTARE) and a neuraminidase (ON) the following of virus strains:  And (H3N2) of 15 mkg of HECTARE; And (H1N1) of 15 mkg of HECTARE; B of 15 mkg of HECTARE

Excipients: potassium chloride; potassium dihydrophosphate; phosphate sodium dihydrate; sodium chloride; Calcii chloridum dihydrate; chloride magnesium hexahydrate; water for injections.

Pharmacological properties:

Pharmacological action - the creating development of specific immunity.

Pharmacodynamics. Creates specific immunity to influenza viruses of types A and B which comes, as a rule, in 14 days after an inoculation and remains till 1 year.

Indications to use:

Prevention of flu at adults and children since 6 months.
Vaccination is recommended to all persons and, first of all, the following categories of the population which are put the increased risk in case of a flu combination to already available diseases/states:
- to persons 65 years regardless of a condition of their health are more senior;
- the patient with diseases of a respiratory organs;
- the patient with cardiovascular diseases of any etiology;
- patient with a chronic renal failure;
- sick diabetes mellitus;
- the patient with immunodeficient diseases (HIV infection, malignant diseases of blood, etc.) and the patient receiving immunodepressants, cytostatics, radiation therapy or high doses of corticosteroids;
- to the children and teenagers (from 6 months to 18 years) receiving for a long time the drugs containing acetylsalicylic acid, and, therefore, subject to the increased risk of development of a syndrome of Ray owing to an influenzal infection;
- to pregnant women (II–III trimester). The pregnant women belonging to the categories which are put the increased risk should be vaccinated irrespective of a pregnancy stage.

Route of administration and doses:

In oil or п / to (deeply). It is strictly forbidden to administer the drug in / century. Immunization is carried out annually to the autumn period. To adults and teenagers (since 14 years) — 0,5 ml once, to children: from 6 months to 3 years — 0,25 ml, from 3 to 14 years — 0,5 ml once; to the children who earlier did not have flu and are not vaccinated and also patients with an immunodeficiency — twice at an interval of 4 weeks.

Features of use:

Drug may contain not defined residual amount of gentamycin therefore at vaccination of persons to aminoglycosides it is necessary to be careful with hypersensitivity.

The vaccine keeps the properties within 12 months. For the expirations of the validity it is considered on June 30 the year following after a year of release. It is not necessary to use after the expiration of the period of validity specified on packaging.

Indications for the handling of one-time syringes.

Before introduction the vaccine has to heat up to room temperature. Just before an injection the syringe it is necessary to stir up, remove a protective cap from a needle and to remove air from the syringe, holding it in vertical position a needle up and slowly pressing the piston. At introduction of a dose of 0,25 ml the movement of the piston of the syringe is stopped at the moment when its internal surface reaches bottom edge of the fixer of a needle.

Side effects:

From circulatory and lymphatic system: seldom — thrombocytopenia.
From immune system: seldom — allergic reactions are possible; very seldom — an acute anaphylaxis.
From a nervous system: often — a headache; seldom — paresthesias, spasms, encephalomyelitis, neuritis, a syndrome to Giyena-Barra.
However convincing data on communication of these reactions with vaccination it is not established.
From vascular system: very seldom — a vasculitis with a tranzitorny renal failure.
General frustration: often — the fatigue and neuralgia which are not demanding treatment and passing in 1–2 days.
Local reactions: reddening, swelling, morbidity, consolidation, ecchymomas.
System reactions: fervescence, an indisposition, a shiver, perspiration, morbidity in muscles and joints.

Indoors, where vaccination is carried out, it is necessary to have HP for treatment of an acute anaphylaxis (adrenaline, glucocorticoids, etc.).

Interaction with other medicines:

Инфлювак® it is possible to apply along with other vaccines (vaccines should be entered into different body parts different syringes). Strengthening of side effects is possible.

If the patient receives immunosuppressive therapy, the immune response can be lowered.

After vaccination obtaining false positive results of serological tests is possible (when carrying out the immune and fermental analysis (IFA) which are caused by development of IgM after vaccination.

Incompatibility: cases of incompatibility are unknown.

Contraindications:

- hypersensitivity to chicken protein or to any other component of a vaccine;
- strong temperature or allergic reactions after the previous vaccination by subunit influenza vaccines.

Vaccination is postponed until the end of acute displays of a disease and an exacerbation of chronic diseases. At not heavy SARS, acute intestinal and other diseases vaccination is carried out at once after normalization of temperature.

Use at pregnancy and feeding by a breast
Experience of use shows that Inflyuvak® has no teratogenic or toxic effect on a fruit. The vaccine Inflyuvak® can be used in the period of a lactation.

Overdose:

There are no data.

Storage conditions:

In the place protected from light, at a temperature of 2-8 °C (not to freeze).
To store in the place, unavailable to children.

Issue conditions:

According to the recipe

Packaging:

In one-time syringes complete with syringe needles on 0,5 ml; in a pack of cardboard 1 or 10 sets.